Category: Uncategorized

EXPANDING 90-DAY OUTPATIENT PRESCRIPTIONS: VIETNAM IS MOVING FROM MONTHLY DISPENSING TOWARD LONG-TERM CHRONIC DISEASE MANAGEMENT

22/09/2026 Published by HealthBiz

Key Development Vietnam’s Ministry of Health is seeking feedback on a draft amendment to Circular 26/2025/TT-BYT that would expand the... Read more

Tags: #Vietnam

FDA APPROVES INLURIYO–VERZENIO: LILLY IS NOT JUST ADDING A COMBINATION — IT IS DEFENDING AN ENTIRE BREAST CANCER FRANCHISE

21/09/2026 Published by HealthBiz

Key Development 11.1 months versus 5.5 months. That was median progression-free survival for Inluriyo plus Verzenio compared with Inluriyo alone... Read more

Category: Uncategorized

Tags: #Global Trends

RETENSION AND TREX BIO FILE FOR IPOs: THE BIOTECH CAPITAL WINDOW IS OPEN — BUT IT IS NO LONGER FORGIVING

21/09/2026 Published by HealthBiz

Key Development Two biotechs filed for IPOs on the same day, yet one held nearly $91 million of cash and... Read more

Category: Uncategorized

Tags: #Global Trends

NOVO DOES NOT NEED ANOTHER OBESITY DRUG — IT NEEDS A GROWTH ENGINE THAT IS ACTUALLY INDEPENDENT

21/09/2026 Published by HealthBiz

Key Development Nearly 94% of Novo Nordisk's 2025 revenue came from diabetes and obesity. That concentration explains why investors are... Read more

Category: Uncategorized

Tags: #Global Trends

MABXIENCE–SANDOZ AND THE $5.7 BILLION EMICIZUMAB MARKET: BIOSIMILARS ARE MOVING INTO THE HARDER END OF RARE DISEASE

21/09/2026 Published by HealthBiz

Key Development A reference market worth an estimated $5.7 billion is being targeted by a biosimilar still in early-stage development.... Read more

Category: Uncategorized

Tags: #Global Trends

SPLITTING CHILDHOOD VACCINES INTO MORE DOSES: THE BIGGER QUESTION IS NOT SHOT COUNT — IT IS WHETHER CHILDREN COMPLETE THE SCHEDULE

21/09/2026 Published by HealthBiz

Key Development Turning one vaccination encounter into five doses delivered six months apart would change far more than the injection... Read more

Category: Uncategorized

Tags: #Global Trends

TELIX’S $1.65 BILLION ACQUISITION OF ITM: SECURING INFRASTRUCTURE SUPREMACY IN RADIOPHARMACEUTICALS

21/09/2026 Published by HealthBiz

Key Development Australia-based Telix Pharmaceuticals has entered into a definitive agreement to acquire German radiopharmaceutical manufacturer ITM Isotope Technologies Munich... Read more

Category: Uncategorized

Tags: #M&A